The substantia nigra in Parkinson's disease (PD) is depleted of dopaminergic neurons and
contains fibrillar Lewy bodies comprising primarily α-synuclein. We screened a library to …

α-, β-, and γ-Synuclein, a novel family of neuronal proteins, has become the focus of
research interest because α-synuclein has been increasingly implicated in the pathogenesis …

The two current major staging systems in use for Lewy body disorders fail to classify up to
50% of subjects. Both systems do not allow for large numbers of subjects who have Lewy …

Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and
amyotrophic lateral sclerosis (ALS), are characterized by the death of neurons within specific …

Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative
dementia in older people. It is part of the range of clinical presentations that share a neuritic …

Parkinson's disease is a widespread degenerative illness affecting the human central,
peripheral, and enteric nervous systems. The underlying pathological process progresses …

The substantia nigra is not the induction site in the brain of the neurodegenerative process
underlying Parkinson disease (PD). Instead, the results of this semi-quantitative study of 30 …

Antibodies to α‐synuclein (AS) now provide a sensitive and specific method for the detection
of Lewy bodies (LBs) and their use will allow a more accurate determination of the …

Direct targeting of alpha-synuclein (ASYN) has emerged as a disease-modifying strategy for
Parkinson's disease and other synucleinopathies which is being approached using both …

Parkinson's disease (PD) is recognized by the accumulation of α-synuclein within neurons.
In contrast to the current ascending theory where α-synuclein would propagate from neuron …